Home NLENAAAA

Caelus Health announces first closing of a Series A financing round to advance microbiota-based therapeutics for cardio-metabolic disorders

Caelus Health has secured €2.5 million in a Series A investment round, enabling the company to advance its pipeline of microbiota-based products for early intervention in cardio-metabolic disease.

Caelus Health
is an AMC spin-off and one of the first companies fully dedicated to the clinical development of microbiota-based products for early intervention in cardio-metabolic disease. Caelus was founded in 2014 by prof. Max Nieuwdorp (Academic Medical Centre, AMC, Amsterdam) and prof. Willem M. De Vos (Wageningen University), based on the initial work with fecal transplant studies in the AMC.

Read more in the press release.